Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
29.46
+0.74 (2.58%)
At close: Jun 12, 2026, 4:00 PM EDT
29.94
+0.48 (1.63%)
Pre-market: Jun 15, 2026, 7:39 AM EDT
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $20.75M in the quarter ending March 31, 2026, with 137.75% growth. This brings the company's revenue in the last twelve months to $66.05M, up 78.34% year-over-year. In the year 2025, Agios Pharmaceuticals had annual revenue of $54.03M with 48.03% growth.
Revenue (ttm)
$66.05M
Revenue Growth
+78.34%
P/S Ratio
26.53
Revenue / Employee
$122,311
Employees
540
Market Cap
1.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.03M | 17.53M | 48.03% |
| Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
| Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
| Dec 31, 2022 | 14.24M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 94.39M | 51.38M | 119.45% |
| Dec 31, 2017 | 43.01M | -26.88M | -38.46% |
| Dec 31, 2016 | 69.89M | 10.77M | 18.22% |
| Dec 31, 2015 | 59.12M | -6.24M | -9.55% |
| Dec 31, 2014 | 65.36M | 39.81M | 155.82% |
| Dec 31, 2013 | 25.55M | 442.00K | 1.76% |
| Dec 31, 2012 | 25.11M | 3.27M | 14.97% |
| Dec 31, 2011 | 21.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 420.69M |
| Iovance Biotherapeutics | 285.61M |
| Nuvation Bio | 143.05M |
| Nurix Therapeutics | 71.78M |
| Viridian Therapeutics | 70.92M |
| Intellia Therapeutics | 66.09M |
| Mesoblast | 65.38M |
| Nanobiotix | 38.27M |
AGIO News
- 2 hours ago - Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright - TheFly
- 16 hours ago - Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat - TheFly
- 1 day ago - Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease - GlobeNewsWire
- 1 day ago - Agios Pharmaceuticals Transcript: EHA 2026 - Transcripts
- 1 day ago - Agios Pharmaceuticals Slides: FY 2026 - Filings
- 4 days ago - Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan - TheFly
- 14 days ago - Agios Pharmaceuticals Transcript: Status update - Transcripts
- 14 days ago - Agios Pharmaceuticals Slides: Status update - Filings